Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Charles Conrad
University of Tx Md Anderson Can Ctr, Department: Neurosurgery
Should you be removed from our database? Contact us at [email protected]. Read more below.
Moleculin
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Project #4 of the above-referenced SPORE Grant uses intellectual property licensed to Moleculin for use. Dr. Conrad holds an ownership stake in this privately-held entity. The above-referenced research is focused on the study of brain tumors, and Moleculin is solely focused on the application of this compound in skin disorders (e.g., psoriasis). However, it is my determination that the company could still potentially benefit from research using this compound in other applications (e.g., by sublicensing to another company). Additionally, the research involving this Moleculin-licensed compound is progressing to human subjects research. Dr. Conrad will be a collaborator on pending human subjects research (2012-0358) supported by the Brain Cancer SPORE grant (he will not analyze the data from such research).
Given these facts, I have determined that Dr. Conrad now has a Financial Conflict of Interest with all research using Moleculin-licensed compounds (including the study referenced above).
Dr. Conrad has had a Conflict Management Plan in place for Moleculin since 2006, to address any potential conflicts related to the licensing of this intellectual property. His Plan has now been formally amended in order to address the recent determination of a FCOI with the above-referenced research.
SPORE in Brain Cancer
Over the past 20 years, advances in the treatment of glioblastoma, the most common malignant brain tumor, have been only incremental. If successful, the research proposed in this Brain Cancer SPORE grant will legitimize novel, mechanistically unique therapeutic approaches and validate prognostic and predictive biomarkers, and thereby change the standards of care of patients with brain tumors.
Filed on February 26, 2014.
Tell us what you know about Charles Conrad's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Charles Conrad”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Charles Conrad | University of Tx Md Anderson Can Ctr | Conflict of Interest | Moleculin | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.